Clinical Trials Using A2B Receptor Antagonist PBF-1129

Clinical trials are research studies that involve people. The clinical trials on this list are studying A2B Receptor Antagonist PBF-1129. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trial 1 of 1
  • PBF-1129 in Patients With NSCLC

    Phase I clinical trial in Eastern Cooperative Oncology Group (ECOG) 0-1 patients with locally advanced or metastatic NSCLC to evaluate safety and tolerability of the compound PBF-1129, an Adenosine A2b receptor antagonist. The phase I dose escalation will be conducted 3+3 method. Pharmacokinetic (PK) data will be also obtained.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio